The United States Patent and Trademark Office has officially granted Patent No. 12,616,728 to Super Critical IP, LLC for their cutting-edge invention titled “Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same.” This newly issued patent marks a major milestone in natural medicine and chemical extraction technology, offering pharmaceutical manufacturers, natural supplement developers, and laboratory technicians a highly scalable, efficient, and cost-effective conversion platform.
According to the official patent documentation, the extraction and conversion system features a conversion reactor configured to process a starting composition containing a cannabinoid combined with a specialized C9 to C11 non-aromatic hydrocarbon solvent, such as n-decane, and a subsequent crystallization unit. The foundational breakthrough of this system rests on its ability to chemically convert a specific portion of the primary cannabinoid into a target derivative, after which the unreacted starting material is systematically precipitated out via temperature reduction and isolated, allowing the desired derivative to be cleanly harvested from the remaining mother liquor.
Why the Invention Is Truly Innovative
Traditional chemical modification of cannabinoids, such as transforming abundant cannabidiol (CBD) into rarer or more potent therapeutic derivatives, frequently suffers from severe manufacturing bottlenecks. Conventional conversion processes often rely on harsh acids, volatile aromatic solvents like benzene or toluene, and slow chromatographic separation methods to isolate the final product. These legacy methods generate significant amounts of hazardous chemical waste, require immense operational energy, and typically result in poor yields or low-purity extracts filled with unwanted byproducts that are difficult to filter out at a commercial scale.
The solution developed by Super Critical IP, LLC removes these traditional manufacturing constraints completely. By implementing a process that utilizes a C9 to C11 non-aromatic hydrocarbon solvent (specifically n-decane) within a highly controlled conversion reactor, the system achieves an intentional partial conversion rate between 10 percent and 90 percent. Instead of forcing an exhaustive and messy single-pass conversion, the reaction mixture is routed into a dedicated crystallization unit. Lowering the temperature causes at least 50 percent of the unreacted starting cannabinoid to cleanly precipitate out as solids, allowing it to be filtered and recycled back into the system. Meanwhile, the high-purity target cannabinoid derivative stays dissolved in the remaining mother liquor, allowing for simple, efficient, and highly scalable isolation without the need for destructive chromatography.
Recognized as June 2026 Patent of the Month
This groundbreaking chemical extraction methodology has earned the prestigious “Patent of the Month” distinction for June 2026 within the global natural-medicine industry. The selection committee highly commended the invention for bridging the gap between organic botanical sourcing and rigorous pharmaceutical standards. By prioritizing non-aromatic hydrocarbon solvents like n-decane and establishing a closed-loop recycling mechanism for unreacted starting materials, the system drastically slashes the carbon and chemical footprint typically associated with cannabinoid synthesis.
Furthermore, the industry wide impact on manufacturing standardization played a major role in securing this accolade. In the natural medicine sector, maintaining strict batch consistency and product purity is a major operational challenge. The committee noted that this design provides laboratories with a highly predictable, repeatable mechanical framework to manufacture rare, therapeutic cannabinoid derivatives. By eliminating reliance on toxic aromatic compounds, the patent ensures that natural medicine distributors can supply consumer-safe, ultra-pure inputs that meet rigid international safety standards while maximizing overall production throughput.
U.S. R&D Tax Credit Eligibility and Practical Applications
From a commercial and corporate development perspective, the practical engineering work associated with developing this cannabinoid conversion and isolation system provides an excellent pathway for companies looking to claim the United States Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41. To qualify for these valuable federal tax incentives, the development activities must satisfy a strict four-part test: the work must be technological in nature, target the creation or improvement of a business component’s function, eliminate technical uncertainty, and involve a systematic process of experimentation. Natural medicine laboratories, biotechnology firms, and specialized extraction companies can qualify for substantial tax savings by thoroughly documenting their engineering iterations. Eligible activities include conducting thermodynamic modeling to map the precise cooling curves required to precipitate unreacted compounds, experimenting with various reactor conditions to optimize the conversion ratio, and executing strict chemical testing to verify that all traces of hydrocarbon solvents are completely removed from the final mother liquor. Additionally, constructing pilot-scale crystallization assemblies and running trial batches to eliminate technical uncertainty regarding crystallization kinetics represent classic qualified research expenses (QREs) that directly support a successful R&D tax credit application.
